Archives of Pediatric Infectious Diseases

Published by: Kowsar

Drug-Resistant Tuberculosis and Group 5 Anti-Tuberculosis Drugs

Shervin Shokouhi 1 , * and Ilad Alavi Darazam 1 , 2
Authors Information
1 Department of Infectious Diseases and Tropical Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Alimoradian Hospital, Hamadan University of Medical Sciences, Hamadan, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: January 01, 2015, 3 (1 TB); e22997
  • Published Online: January 26, 2015
  • Article Type: Editorial
  • Received: August 23, 2014
  • Accepted: August 27, 2014
  • DOI: 10.5812/pedinfect.22997

To Cite: Shokouhi S, Alavi Darazam I. Drug-Resistant Tuberculosis and Group 5 Anti-Tuberculosis Drugs, Arch Pediatr Infect Dis. 2015 ; 3(1 TB):e22997. doi: 10.5812/pedinfect.22997.

Copyright © 2015, Pediartric Infections Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnote
References
  • 1. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993; 328(8): 521-6[DOI][PubMed]
  • 2. Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med. 2014; [DOI][PubMed]
  • 3. Global tuberculosis control: WHO report 2011. 2011;
  • 4. Global tuberculosis report 2013. 2013;
  • 5. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest. 2009; 136(2): 420-5[DOI][PubMed]
  • 6. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013; 368(8): 745-55[DOI][PubMed]
  • 7. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013; 207(9): 1352-8[DOI][PubMed]
  • 8. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182(5): 684-92[DOI][PubMed]
  • 9. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008; 359(6): 563-74[DOI][PubMed]
  • 10. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013; 68(2): 284-93[DOI][PubMed]
  • 11. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012; 16(4): 447-54[DOI][PubMed]
  • 12. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367(16): 1508-18[DOI][PubMed]
  • 13. Kurz SG, Wolff KA, Hazra S, Bethel CR, Hujer AM, Smith KM, et al. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis beta-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of beta-lactam-beta-lactamase inhibitor combinations. Antimicrob Agents Chemother. 2013; 57(12): 6085-96[DOI][PubMed]
  • 14. Gonzalo X, Drobniewski F. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother. 2013; 68(2): 366-9[DOI][PubMed]
  • 15. Sullivan T, Ben Amor Y. What's in a name? The future of drug-resistant tuberculosis classification. Lancet Infect Dis. 2013; 13(4): 373-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments